Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 2:00 AM
Ignite Modification Date:
2025-12-25 @ 2:00 AM
NCT ID:
NCT06319794
Brief Summary:
The aim of the study is to evaluate efficacy and safety of bimiralisib gel treatment for treatment of actinic keratosis (AK) on the face and/or scalp and/or back of hands
Detailed Description:
This is a multi-center, randomized, open label, parallel group study. The study products will be applied to the target lesions for a duration of 2 or 4 weeks of treatment.
The study consists of the following periods:
* Screening (up to 30 days)
* Treatment (2 or 4 weeks)
* Follow-Up (4 weeks)
Participants will be randomized to one of two groups (1:1):
* Arm A: Topical bimiralisib gel treatment for 2 weeks
* Arm B: Topical bimiralisib gel treatment for 4 weeks
Study:
NCT06319794
Study Brief:
Protocol Section:
NCT06319794